OncoMatch/Clinical Trials/NCT06492421
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.
Is NCT06492421 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab for lung cancer.
Treatment: ipilimumab, pembrolizumab, durvalumab, idarubicin, bevacizumab — This phase II trial studies how well intra-tumor injection of double checkpoint inhibitors work when given alone and in combination with chemotherapy or/and bevacizumab in treating patients with previously untreated stage I-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as ipilimumab, pembrolizumab or durvalumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Drugs used in interventional radiological chemotherapy, such as idabubicin, can directly kill the cancer cell and release tumor antigens to activate DC function in situ. Giving intra-tumor injection of checkpoints inhibitors with or without chemotherapy and/or bevecizumab may work better than in vein infusion of the drugs in treating patients with non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Prior systemic therapy or radiation therapy for treatment of the current lung cancer
Cannot have received: radiation therapy
Prior systemic therapy or radiation therapy for treatment of the current lung cancer
Cannot have received: chemotherapy
Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug
Cannot have received: immunotherapy
Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug
Cannot have received: biologic therapy
Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drug
Cannot have received: anti-PD-1 therapy
Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody
Cannot have received: anti-PD-L1 therapy
Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody
Cannot have received: anti-CTLA-4 therapy
Prior treatment with an anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibody
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L; Hemoglobin ≥ 8.0 g/dL; Platelets ≥ 100 x 10^9/L
Kidney function
Creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 mL/min using Cockcroft-Gault formula OR 24-hour urine creatinine clearance ≥ 50 mL/min
Liver function
Total bilirubin ≤ 1.5 x ULN (except subjects with Gilbert syndrome who can have total bilirubin < 3.0 mg/dL)
ANC ≥ 1.5 x 10^9/L; Hemoglobin ≥ 8.0 g/dL; Platelets ≥ 100 x 10^9/L; Total bilirubin ≤ 1.5 x ULN (except subjects with Gilbert syndrome who can have total bilirubin < 3.0 mg/dL); Creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 mL/min using Cockcroft-Gault formula for creatinine clearance calculation OR 24-hour urine creatinine clearance ≥ 50 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify